Fulcrum Therapeutics, Inc. (FULC) Bundle
A Brief History of Fulcrum Therapeutics, Inc. (FULC)
Company Formation and Early Development
Company Formation and Early Development
Fulcrum Therapeutics, Inc. was founded in 2015, focusing on genetic diseases with significant unmet medical needs. The company is based in Cambridge, Massachusetts. In its early years, Fulcrum leveraged a drug discovery platform to identify novel therapeutics aimed at rare diseases, particularly those caused by underlying genetic mutations.
Initial Funding Rounds
Fulcrum Therapeutics successfully raised $60 million in a Series A funding round in 2016. The round was led by New Enterprise Associates, with participation from other investors such as F-Prime Capital Partners and Acorn Fund.
Research and Development Progress
In 2018, Fulcrum initiated Phase 1 clinical trials for its lead drug candidate, FK-506, targeting the treatment of Duchenne Muscular Dystrophy (DMD). The drug was designed to modulate the expression of utrophin, a protein that can compensate for the absence of dystrophin in DMD patients.
Public Offering
On April 25, 2019, Fulcrum Therapeutics went public with its Initial Public Offering (IPO), raising approximately $102 million by offering 6.5 million shares at $16 per share. This event marked a significant milestone for the company, enhancing its financial position for subsequent R&D.
Financial Performance
| Year | Revenue (in millions) | Net Income (in millions) | Total Assets (in millions) | Total Liabilities (in millions) |
|---|---|---|---|---|
| 2019 | $0.3 | ($27.1) | $110.1 | $35.3 |
| 2020 | $0.5 | ($32.7) | $120.4 | $48.1 |
| 2021 | $1.2 | ($41.3) | $156.8 | $69.3 |
| 2022 | $1.8 | ($34.9) | $201.7 | $78.6 |
| 2023 (Q2) | $2.5 | ($15.7) | $210.5 | $85.4 |
Strategic Partnerships
Fulcrum has also established collaborations with various institutions to bolster its drug development initiatives. In 2020, it entered a partnership with UConn Health to advance research in ultra-rare genetic diseases.
Clinical Trials and Drug Development
As of October 2023, Fulcrum is advancing several drug candidates through clinical trials, including FHD-401, targeting Friedreich's Ataxia, which is in Phase 2 trials. The company has announced plans to broaden its pipeline to include additional genetic disorders.
Regulatory Milestones
In 2022, Fulcrum received Fast Track designation from the FDA for its lead candidate, reflecting its potential to address significant medical needs. This designation facilitates expedited development and review processes.
Market Position and Future Outlook
Fulcrum Therapeutics currently trades on the Nasdaq under the ticker symbol FULC. As of October 2023, the company's market capitalization stands at approximately $400 million. Analysts project significant growth due to its promising pipeline and strategic expansions.
Recent Developments
In Q2 2023, Fulcrum announced a strategic acquisition of a promising preclinical asset for an undisclosed amount, further diversifying its therapeutic focus. The ongoing clinical trials and research endeavors position the company well in the biopharmaceutical landscape.
A Who Owns Fulcrum Therapeutics, Inc. (FULC)
Ownership Structure
Ownership Structure
As of the most recent available data, Fulcrum Therapeutics, Inc. (FULC) has a diversified ownership structure. This includes institutional investors, insiders, and retail shareholders.
Major Institutional Shareholders
| Institution | Ownership (%) | No. of Shares Held |
|---|---|---|
| BlackRock, Inc. | 10.12% | 1,504,257 |
| The Vanguard Group, Inc. | 9.63% | 1,416,987 |
| State Street Corporation | 7.47% | 1,102,184 |
| Geode Capital Management, LLC | 3.85% | 571,894 |
| Invesco Ltd. | 3.01% | 448,395 |
Insider Ownership
Insider ownership consists of executives and board members holding a significant amount of shares.
| Name | Position | Ownership (%) | No. of Shares Held |
|---|---|---|---|
| Robert G. Johnson | CEO | 2.25% | 332,500 |
| F. Thomas O'Neill | CFO | 1.15% | 170,000 |
| Mark T. B. Smith | Director | 0.85% | 125,000 |
Retail Ownership
Retail investors typically represent a smaller portion of Fulcrum Therapeutics' ownership but can still influence market dynamics.
| Investor Type | Ownership (%) | No. of Shares Held |
|---|---|---|
| Retail Investors | 28.0% | 4,164,000 |
Recent Financial Metrics
As of the latest quarter, Fulcrum Therapeutics reported the following financial metrics which may influence ownership decisions:
| Metric | Value |
|---|---|
| Market Capitalization | $104 million |
| Revenue (Last Fiscal Year) | $5.6 million |
| Net Loss (Last Fiscal Year) | -$38 million |
| Cash and Cash Equivalents | $50 million |
Fulcrum Therapeutics, Inc. (FULC) Mission Statement
Core Mission
Fulcrum Therapeutics, Inc. is dedicated to developing innovative therapies for patients with genetically driven diseases. The company's mission focuses on:
- Understanding the biology of diseases.
- Developing treatments that target underlying genetic causes.
- Improving patient outcomes and quality of life.
Strategic Objectives
Fulcrum aims to achieve its mission through a robust strategy that includes:
- Advancing clinical development programs.
- Strengthening partnerships with academic and industry leaders.
- Maximizing the value of its proprietary platform.
Recent Financial Performance
As of Q2 2023, Fulcrum Therapeutics reported key financial metrics:
| Metric | Value |
|---|---|
| Total Revenue | $5.1 million |
| Net Loss | ($8.3 million) |
| Cash and Cash Equivalents | $55.2 million |
| Research and Development Expenses | $9.7 million |
Product Pipeline
Fulcrum Therapeutics’ product pipeline includes:
- FAP-226: Currently in Phase 2 clinical trials for fascioscapulohumeral muscular dystrophy (FSHD).
- FAP-309: Investigational candidate in development for Duchenne muscular dystrophy (DMD).
- Licensing Agreements: Collaborations with several biopharmaceutical companies to enhance research capabilities.
Commitment to Innovation
Fulcrum is committed to scientific innovation which is reflected in:
- The establishment of a scientific advisory board comprising leading experts in genetics.
- Investment in technology platforms for drug discovery and development.
- Collaboration with patient advocacy groups to align research with patient needs.
Market Position and Future Outlook
Fulcrum Therapeutics operates in a competitive landscape with a focus on unmet medical needs:
| Category | Value |
|---|---|
| Total Market Size for Genetic Therapies (2023) | $12 billion |
| Projected CAGR (2023-2028) | 31.5% |
| Number of Active Competitors | Approximately 25 |
Community Engagement
Fulcrum Therapeutics places a strong emphasis on community and patient engagement:
- Regular updates and interactions with patient communities.
- Educational initiatives related to genetic disorders.
- Support programs for patients and families affected by rare diseases.
How Fulcrum Therapeutics, Inc. (FULC) Works
Company Overview
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing transformative therapies for patients with genetically driven diseases. The company is headquartered in Cambridge, Massachusetts.
Key Financials
As of Q3 2023, Fulcrum Therapeutics reported the following financial metrics:
| Financial Metric | Amount (in millions USD) |
|---|---|
| Cash and Cash Equivalents | 74.3 |
| Total Assets | 115.6 |
| Total Liabilities | 28.4 |
| Total Revenue | 0.0 |
| Net Loss | (34.6) |
Research and Development Focus
Fulcrum's pipeline consists of several development programs:
- FAP-101 for Duchenne muscular dystrophy (DMD)
- FAP-251 for myotonic dystrophy type 1 (DM1)
- FAP-201 for facioscapulohumeral muscular dystrophy (FSHD)
Recent Developments
In September 2023, Fulcrum Therapeutics announced the initiation of a Phase 2 clinical trial for FAP-101, targeting DMD patients. The trial aims to enroll approximately 120 participants across multiple sites.
Stock Performance
As of October 2023, the stock price of Fulcrum Therapeutics (FULC) is approximately $3.25, with a market capitalization of about $120 million. The stock has fluctuated between $2.85 and $4.10 over the last six months.
Collaborations and Partnerships
Fulcrum Therapeutics has entered into collaborative agreements with several leading academic institutions and biotech firms:
- Collaboration with the University of California, San Diego for DMD research
- Partnership with a global pharmaceutical company for clinical development
Intellectual Property
Fulcrum holds multiple patents related to its drug candidates, with a primary focus on methods of treating genetic muscular dystrophies. The patent portfolio includes:
| Patent Focus | Status | Expiration Year |
|---|---|---|
| FAP-101 | Granted | 2035 |
| FAP-251 | Pending | N/A |
| FAP-201 | Granted | 2034 |
Management Team
The management team of Fulcrum Therapeutics consists of experienced professionals in biopharmaceutical development:
- Chief Executive Officer: Robert O. W. Krevets
- Chief Financial Officer: Jane L. Smith
- Chief Medical Officer: Mark A. Davis
Future Outlook
Fulcrum Therapeutics plans to advance its pipeline towards commercialization, with anticipated milestones over the next year including:
- Completion of Phase 2 trials for FAP-101
- Initiation of Phase 1 trials for FAP-251
How Fulcrum Therapeutics, Inc. (FULC) Makes Money
Revenue Generation Through Clinical Development
Fulcrum Therapeutics focuses on developing therapies for rare diseases, particularly conditions related to muscle disorders. Their primary revenue generation is through partnerships and collaborations for the development of innovative treatments. As of Q3 2023, the company reported a collaboration agreement with Bristol Myers Squibb, which includes potential milestone payments and royalties on future sales.
Collaborative Partnerships
Fulcrum's strategic collaborations have led to significant financial contributions. For example, the company received a milestone payment of $10 million in early 2023 from their collaboration with Pfizer for advancing clinical trials. Additionally, such collaborations often include performance-based milestones, which can sum up to hundreds of millions of dollars depending on the success of the drugs in development.
Grants and Funding
In 2022, Fulcrum Therapeutics secured a grant from the National Institutes of Health (NIH) totaling $5 million to expedite research on its lead candidate, FTX-6058. This funding aids in defraying research costs while also bolstering the company's financial stability during the clinical trial phases.
Equity Financing
In 2021, Fulcrum Therapeutics completed a public offering raising approximately $50 million. This funding has been crucial in advancing their pipeline and maintaining operational liquidity. As of September 2023, the company reported a cash and cash equivalents balance of $75 million, which is essential for ongoing clinical trials and operational expenses.
Product Pipeline and Future Revenue Projections
Fulcrum's product pipeline includes several candidates, with FTX-6058 targeting sickle cell disease. The market for treatments in this area is projected to reach $4 billion by 2028, providing a substantial revenue opportunity for Fulcrum if their treatments are approved and commercialized.
Table of Financial Overview
| Year | Revenue ($ millions) | Operating Expenses ($ millions) | Net Income/Loss ($ millions) | Cash and Cash Equivalents ($ millions) |
|---|---|---|---|---|
| 2019 | 0 | 30 | -30 | 50 |
| 2020 | 0 | 38 | -38 | 40 |
| 2021 | 20 | 45 | -25 | 50 |
| 2022 | 15 | 50 | -35 | 25 |
| 2023 (Q3) | 5 | 35 | -30 | 75 |
Royalties and Milestone Payments
Fulcrum stands to gain considerable revenue through milestone payments from partnerships. For example, additional milestone payments from the Bristol Myers Squibb collaboration could exceed $200 million if certain regulatory and sales targets are achieved.
Market Forecasts
The market for rare disease treatments is projected to grow substantially. Analysts predict that by 2030, the global rare disease market may reach $250 billion, which provides a promising landscape for Fulcrum's therapeutic developments.
Fulcrum Therapeutics, Inc. (FULC) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support